Clinical characteristics and management of late urinary symptom flare following stereotactic body radiation therapy for prostate cancer

Frontiers in Oncology

Volumn 4 MAY, Issue , 2014, Pages

  Woo, Jennifer A ^a   Chen, Leonard N ^a   Bhagat, Aditi ^a   Oermann, Eric K ^a   Kim, Joy S ^a   Moures, Rudy ^a   Yung, Thomas ^a   Lei, Siyuan ^a   Collins, Brian T ^a   Kumar, Deepak ^b   Suy, Simeng ^a   Dritschilo, Anatoly ^a   Lynch, John H ^a   Collins, Sean P ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF THE DISTRICT OF COLUMBIA   (United States)

Author keywords

AUA symptom score; Bother; CyberKnife; EPIC; Genitourinary toxicity; Late urinary symptom flare; Prostate cancer; SBRT

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANALGESIC AGENT; CORTICOSTEROID; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; AMERICAN UROLOGICAL ASSOCIATION SYMPTOM INDEX; ARTICLE; CYBERKNIFE; DISEASE SEVERITY; DYSURIA; FOLLOW UP; HEMATURIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROSTATE CANCER; RADIATION DOSE; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT PLANNING; URINARY FREQUENCY; URINARY TRACT DISEASE; URINARY URGENCY; URINE INCONTINENCE; URINE RETENTION; VERY ELDERLY;

EID: 84904681458     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00122     Document Type: Article

References (48)

1. Bekelman JE, Mitra N, Efstathiou J, Liao K, Sunderland R, Yeboa DN, et al. Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys (2011) 81:e325-34. doi: 10.1016/j.ijrobp.2011.02.006
2. Michalski JM, Yan Y, Watkins-Bruner D, Bosch WR, Winter K, Galvin JM, et al. Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial. Int J Radiat Oncol Biol Phys (2013) 87:932-8. doi:10.1016/j.ijrobp.2013.07.041
3. Peeters ST, Heemsbergen WD, Koper PC, Van Putten WL, Slot A, Dielwart MF, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol (2006) 24:1990-6. doi:10.1200/JCO.2005.05.2530
4. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys (2008) 70:67-74. doi:10.1016/j.ijrobp.2007.06.054
5. Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys (2008) 70:1124-9. doi:10.1016/j.ijrobp.2007.11.044
6. Ahmed AA, Egleston B, Alcantara P, Li L, Pollack A, Horwitz EM, et al. A novel method for predicting late genitourinary toxicity after prostate radiation therapy and the need for age-based risk-adapted dose constraints. Int J Radiat Oncol Biol Phys (2013) 86:709-15. doi:10.1016/j.ijrobp.2013.03.020
7. Devisetty K, Zorn KC, Katz MH, Jani AB, Liauw SL. External beam radiation therapy after transurethral resection of the prostate: a report on acute and late genitourinary toxicity. Int J Radiat Oncol Biol Phys (2010) 77:1060-5. doi:10.1016/j.ijrobp.2009.06.078
8. Chen LN, Suy S, Uhm S, Oermann EK, Ju AW, Chen V, et al. Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol (2013) 8:58. doi:10.1186/1748-717X-8-58
9. Schmid MP, Potter R, Bombosch V, Sljivic S, Kirisits C, Dorr W, et al. Late gastrointestinal and urogenital side-effects after radiotherapy - incidence and prevalence. Subgroup-analysis within the prospective Austrian-German phase II multicenter trial for localized prostate cancer. Radiother Oncol (2012) 104:114-8. doi:10.1016/j.radonc.2012.05.007
10. Peters LJ, Withers HR, Brown BW. Complicating issues in complication reporting. Int J Radiat Oncol Biol Phys (1995) 31:1349-51. doi:10.1016/0360-3016(95)00041-V
11. Sonn GA, Sadetsky N, Presti JC, Litwin MS. Differing perceptions of quality of life in patients with prostate cancer and their doctors. J Urol (2013) 189:S59-65. doi:10.1016/j.juro.2012.11.032
12. Gelblum DY, Potters L, Ashley R, Waldbaum R, Wang XH, Leibel S. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys (1999) 45:59-67. doi:10.1016/S0360-3016(99)00176-5
13. Merrick GS, Butler WM, Lief JH, Dorsey AT. Temporal resolution of urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys (2000) 47:121-8. doi:10.1016/S0360-3016(99)00525-8
14. Cesaretti JA, Stone NN, Stock RG. Urinary symptom flare following I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys (2003) 56:1085-92. doi:10.1016/S0360-3016(03)00210-4
15. Crook J, Fleshner N, Roberts C, Pond G. Long-term urinary sequelae following 125iodine prostate brachytherapy. J Urol (2008) 179:141-145; discussion 146. doi:10.1016/j.juro.2007.08.136
16. Keyes M, Miller S, Moravan V, Pickles T, Liu M, Spadinger I, et al. Urinary symptom flare in 712 125I prostate brachytherapy patients: long-term follow-up. Int J Radiat Oncol Biol Phys (2009) 75:649-55. doi:10.1016/j.ijrobp.2008.11.043
17. Suy S, Oermann E, Hanscom H, Lei S, Vahdat S, Yu X, et al. Histopathologic effects of hypofractionated robotic radiation therapy on malignant and benign prostate tissue. Technol Cancer Res Treat (2010) 9:583-7. doi:10.7785/tcrt.2012.500168
18. Litwin MS, Gore JL, Kwan L, Brandeis JM, Lee SP, Withers HR, et al. Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer (2007) 109:2239-47. doi:10.1002/cncr.22676
19. Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol (2011) 6:3. doi:10.1186/1748-717X-6-3
20. King CR, Brooks JD, Gill H, Presti JC Jr. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys (2011) 82:877-82. doi:10.1016/j.ijrobp.2010.11.054
21. McBride SM, Wong DS, Dombrowski JJ, Harkins B, Tapella P, Hanscom HN, et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer (2012) 118:3681-90. doi:10.1002/cncr.26699
22. Katz AJ, Santoro M, Diblasio F, Ashley R. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat Oncol (2013) 8:118. doi:10.1186/1748-717X-8-118
23. King CR, Collins S, Fuller D, Wang PC, Kupelian P, Steinberg M, et al. Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials. Int J Radiat Oncol Biol Phys (2013) 87:939-45. doi:10.1016/j.ijrobp.2013.08.019
24. King CR, Freeman D, Kaplan I, Fuller D, Bolzicco G, Collins S, et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol (2013) 109:217-21. doi:10.1016/j.radonc.2013.08.030
25. Lei S, Piel N, Oermann EK, Chen V, Ju AW, Dahal KN, et al. Six-dimensional correction of intra-fractional prostate motion with cyberknife stereotactic body radiation therapy. Front Oncol (2011) 1:48. doi:10.3389/fonc.2011.00048
26. Oermann EK, Suy S, Hanscom HN, Kim JS, Lei S, Yu X, et al. Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer. J Hematol Oncol (2011) 4:12. doi:10.1186/1756-8722-4-12
27. Katz AJ, Santoro M, Ashley R, Diblasio F. Stereotactic body radiation therapy for low- and low-intermediate-risk prostate cancer: is there a dose effect? Front Oncol (2011) 1:49. doi:10.3389/fonc.2011.00049
28. Xie Y, Djajaputra D, King CR, Hossain S, Ma L, Xing L. Intrafractional motion of the prostate during hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys (2008) 72:236-46. doi:10.1016/j.ijrobp.2008.04.051
29. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol (1992) 148:1549-1557; discussion 1564.
30. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology (2000) 56:899-905. doi:10.1016/S0090-4295(00)00858-X
31. Ciezki JP, Reddy CA, Garcia J, Angermeier K, Ulchaker J, Mahadevan A, et al. PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time. Int J Radiat Oncol Biol Phys (2006) 64:512-7. doi:10.1016/j.ijrobp.2005.07.960
32. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care (2003) 41:582-92. doi:10.1097/00005650-200305000-00007
33. Friedland JL, Freeman DE, Masterson-Mcgary ME, Spellberg DM. Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer. Technol Cancer Res Treat (2009) 8:387-92.
34. Arcangeli G, Fowler J, Gomellini S, Arcangeli S, Saracino B, Petrongari MG, et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2011) 79:1013-21. doi:10.1016/j.ijrobp.2009.12.045
35. Pollack A, Walker G, Horwitz EM, Price R, Feigenberg S, Konski AA, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol (2013) 31:3860-8. doi:10.1200/JCO.2013.51.1972
36. Yu JB, Cramer LD, Herrin J, Soulos PR, Potosky AL, Gross CP. Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity. J Clin Oncol (2014) 32:1195-201. doi:10.1200/JCO.2013.53.8652
37. Ghadjar P, Jackson A, Spratt DE, Oh JH, Munck af Rosenschold P, Kollmeier M, et al. Patterns and predictors of amelioration of genitourinary toxicity after high-dose intensity-modulated radiation therapy for localized prostate cancer: implications for defining postradiotherapy urinary toxicity. Eur Urol (2013) 64:931-8. doi:10.1016/j.eururo.2013.02.001
38. Dorr W, Hendry JH. Consequential late effects in normal tissues. Radiother Oncol (2001) 61:223-31. doi:10.1016/S0167-8140(01)00429-7
39. Movsas B, Raffin TA, Epstein AH, Link CJ Jr. Pulmonary radiation injury. Chest (1997) 111:1061-76. doi:10.1378/chest.111.4.1061
40. Graves PR, Siddiqui F, Anscher MS, Movsas B. Radiation pulmonary toxicity: from mechanisms to management. Semin Radiat Oncol (2010) 20:201-7. doi:10.1016/j.semradonc.2010.01.010
41. Mehta V. Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys (2005) 63:5-24. doi:10.1016/j.ijrobp.2005.03.047
42. Ghafoori P, Marks LB, Vujaskovic Z, Kelsey CR. Radiation-induced lung injury. Assessment, management, and prevention. Oncology (Williston Park) (2008) 22:37-47; discussion 52-33.
43. Ghadjar P, Zelefsky MJ, Spratt DE, Munck af Rosenschold P, Oh JH, Hunt M, et al. Impact of dose to the bladder trigone on long-term urinary function after high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys (2014) 88:339-44. doi:10.1016/j.ijrobp.2013.10.042
44. Prosnitz RG, Schneider L, Manola J, Rocha S, Loffredo M, Lopes L, et al. Tamsulosin palliates radiation-induced urethritis in patients with prostate cancer: results of a pilot study. Int J Radiat Oncol Biol Phys (1999) 45:563-6. doi:10.1016/S0360-3016(99)00246-1
45. Zelefsky MJ, Ginor RX, Fuks Z, Leibel SA. Efficacy of selective alpha-1 blocker therapy in the treatment of acute urinary symptoms during radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys (1999) 45:567-70. doi:10.1016/S0360-3016(99)00232-1
46. Merrick GS, Butler WM, Wallner KE, Lief JH, Galbreath RW. Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy. Urology (2002) 60:650-5. doi:10.1016/S0090-4295(02)01840-X
47. Elshaikh MA, Ulchaker JC, Reddy CA, Angermeier KW, Klein EA, Chehade N, et al. Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: final report of a double-blind placebo-controlled randomized study. Int J Radiat Oncol Biol Phys (2005) 62:164-9. doi:10.1016/j.ijrobp.2004.09.036
48. Symon Z, Daignault S, Symon R, Dunn RL, Sanda MG, Sandler HM. Measuring patients' expectations regarding health-related quality-of-life outcomes associated with prostate cancer surgery or radiotherapy. Urology (2006) 68:1224-9. doi:10.1016/j.urology.2006.08.1092